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Abstract 
Background: More than 100 common variants underlying multiple sclerosis (MS) 
susceptibility have been identified, but their effect on disease phenotype is still largely 
unknown.  
Objective: To assess whether the cumulative genetic risk score of currently known 
susceptibility variants affects clinical presentation. 
Methods: A cumulative genetic risk score was based on four Human Leukocyte Antigen 
(HLA) and 106 non-HLA risk loci genotyped or imputed in 842 Belgian MS patients and 321 
controls. Non-parametric analyses were applied. 
Results: An increased genetic risk is observed for MS patients, including subsets such as 
oligoclonal band negative and primary progressive MS patients, compared to controls. Within 
the patient group, a stronger association between HLA risk variants and the presence of 
oligoclonal bands, an increased IgG index and female gender was apparent.  Results suggest 
an association between a higher accumulation of non-HLA risk variants and increased relapse 
rate as well as shorter relapse-free intervals after disease onset. 
Conclusion: MS patients display a significantly increased genetic risk compared to controls, 
irrespective of disease course or presence of oligoclonal bands. Whereas the cumulative 
burden of non-HLA risk variants appears to be reflected in the relapses of MS patients, the 
HLA region influences intrathecal immunoglobulin G levels.  
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Introduction 
Multiple sclerosis (MS) is a common neuroinflammatory disorder
1
 that mainly affects young 
adults and causes cognitive and physical impairment. Epidemiological studies have shown the 
importance of both genetic and environmental factors in the development of the disease. 
Following the association between the human leukocyte antigen (HLA) region and MS 
susceptibility discovered in the early 1970s, joint efforts during the last decade have led to an 
enormous progress in the identification of additional genetic risk variants.
2-4
 Large-scale 
screens in international study populations, of which the Belgian cohort was a part, have 
identified four classical HLA and 110 non-HLA susceptibility loci.
2-4
 These variants point to 
an important role of the immune system in the pathogenesis of MS, with approximately one 
third of the associated genes having known roles in the immune system and one in five signals 
overlapping with at least one other autoimmune disease.
3
 These variants are common in the 
general population and, with the exception of the HLA region (e.g. HLA-DRB1*15:01: odds 
ratio (OR) = 3.1),
2
 individually exert modest effects (OR: 1.03-1.34).
3
 Since the identification 
of single polymorphisms has proven not to be informative to predict disease outcome, several 
studies have investigated the cumulative effect of combinations of identified risk variants.
5-11
 
Despite results showing it is not applicable for case-control prediction,
5,6,11
 significant 
associations with clinical presentation have been suggested.
8-10
 In this study, we elaborate on 
these previous efforts by calculating MS risk based on the current extended list of MS risk 
variants
2-4
 and investigate the effect on MS phenotype.  
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Methods 
Sample recruitment 
The study cohort consisted of 842 unrelated MS patients and 321 control subjects of 
Caucasian descent. Patients, diagnosed based on Poser
12 
or McDonald
13
 criteria, were 
recruited from the University Hospitals Leuven and the National Multiple Sclerosis Centre 
Melsbroek. Control individuals were spouses of neurological patients, recruited from the same 
population. The study was approved by the Ethics Committee of the University Hospitals 
Leuven and appropriate informed consent was obtained from all participants. Peripheral blood 
samples were taken and DNA was extracted according to standard methods. Clinical 
characteristics (gender, disease course, age at onset, severity, relapse rate, relapse-free interval 
after disease onset, oligoclonal band (OCB) status and count, immunoglobulin G (IgG) index) 
of the study cohort were collected and are presented in Table 1. The annualized baseline 
relapse rate for bout onset MS patients was calculated by dividing the number of relapses that 
occurred before the start of any treatment by the time between the first relapse and the 
initiation of treatment. In order to obtain a representative relapse rate, only patients that were 
followed for more than three months before treatment were included (median follow-up time 
was 6.46 years, ranging from 0.26 to 57.14 years). The relapse-free interval for bout onset MS 
patients was determined by the time between the first and second relapse that occurred before 
the start of any treatment. Severity is measured by the Multiple Sclerosis Severity Score 
(MSSS). Patients were classified as OCB positive when at least two OCBs were present in the 
cerebrospinal fluid (CSF) that were not seen in the serum, otherwise they were classified as 
OCB negative. OCB count represents the number of CSF specific OCBs. The IgG index 
represents the ratio of IgG in the CSF compared to serum, corrected for the presence of 
albumin in both compartments. 
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Table 1. Clinical description of the study cohort.  
Clinical data MS patients N Controls N 
Male : Female, % 35.51 : 64.49 842 47.66 : 52.34 321 
BOMS : PPMS : unknown, % 86.34 : 11.64 : 2.02 842 - - 
AAO (y), median (IQR) 33 (25-41) 822 - - 
MSSS, median (IQR) 6.24 (2.6-8.5)  666 - - 
Relapse rate, median (IQR) 0.54 (0.21-1.12) 252 - - 
Relapse-free interval (y), median (IQR) 2 (0.83-5.08) 231 - - 
OCB positive : OCB negative, % 88.01 : 11.99 559 - - 
OCB count, median (IQR)
 
11 (5.75-15) 260 - - 
IgG index, median (IQR) 0.88 (0.65-1.32) 262 - - 
BOMS: bout onset MS; PPMS: primary progressive MS; AAO: age at onset; y: year; IQR: interquartile range; 
MSSS: MS severity score; OCB: oligoclonal band; IgG index: immunoglobulin G index; N: number of 
individuals. 
 
Single nucleotide polymorphism (SNP) genotyping and imputation 
Cases and controls were genotyped as part of previously published studies.
2,3
 In short, for all 
controls and 309 MS patients, 109/110 non-HLA variants were directly genotyped on the 
Immunochip microarray (Illumina), previously described in detail.
3
 For 538 MS patients 
genotyped on the Human660-Quad chip (Illumina) as part of the 2011 genome-wide 
association study (GWAS),
2
 53/110 SNPs were directly genotyped and all other risk variants 
were imputed with the 1000 Genomes Project European phase I (a) panel using BEAGLE
14
 as 
part of the replication phase of the Immunochip project.
3
 Five case samples were genotyped 
on both platforms and served as an internal control. Variants that were not genotyped or 
imputed in the GWAS dataset were accordingly replaced by the best proxy (r²>0.98; 
Appendix 1) that was also present in the Immunochip dataset, in order to obtain a uniform set 
of SNPs for MS risk calculation. Based on the post-imputation genotype probabilities, 
genotypes were assigned if the probability was higher than 0.6, otherwise they were set to 
missing. SNPs not available for both platforms (rs2150702 in MLANA) or with genotyping 
call rate below 95% (rs2256814 in SLC2A4RG, rs4976646 in RGS14, rs716719 (proxy of 
rs201847125; r²=1) intergenic between C7orf72 and IKZF1) were excluded, leaving 106 non-
HLA risk variants for MS risk calculation (Appendix 1). All variants passed Hardy-Weinberg 
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Equilibrium testing and total genotyping rate in all individuals was 99.83% for the remaining 
non-HLA SNPs. 
HLA genotypes were imputed with HLA*IMP
15
 as part of the original studies (previously 
described in detail).
2,3
 Again, genotypes were assigned when post-imputation genotype 
probabilities were above 0.6 and set to missing if probabilities were below this threshold.  
 
MS risk calculation 
MS risk calculation was based on four classical HLA loci
2
 and 106 of the 110
3
 known non-
HLA susceptibility variants (Appendix 1). To calculate the cumulative genetic risk score, 
corrected odds ratio (ORC) values relative to the population lifetime odds for each genotype 
were determined as previously described in detail by Sawcer and Wason.
16
 
The ORC was calculated by taking into account the frequencies of the risk allele B (frequency: 
p) and the alternate allele b (frequency: q=1-p). ORC for genotypes BB, Bb, bb is given by 
     
   
 
        
  
 
       
 
 
   
where D=OR²p²+OR*2pq+q² and represents the odds ratio between the odds of disease in the 
population as a whole and the odds of disease in the lowest risk genotype.
16
 OR and risk allele 
frequency (RAF) were obtained from the 2011 GWAS
2
 (HLA loci) or Immunochip study
3
 
(non-HLA loci). RAF were based on the frequencies observed in the UK control cohort,
2,3
 
since this was the largest and most closely related control population available. OR point 
estimates were obtained from these previous studies
2,3
 and were determined based on the 
entire study population. The cumulative MS risk score was calculated per sample by summing 
up the natural logarithm of the corrected odds ratio values for each genotype for each of the 
four HLA and 106 non-HLA risk loci. To assess the effect of the HLA region, MS risk was 
calculated based on all risk variants combined or the HLA and non-HLA variants separately. 
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In the rare event that an individual’s genotype for a SNP was missing, the score for that SNP 
was set to zero. Next, the exponent of this summed score was multiplied by the risk of disease 
in all individuals prior to genotyping, i.e. the population prevalence (0.001). This absolute risk 
was used to investigate the association with MS phenotype.  
 
Statistical analysis 
Statistical analysis was performed using R statistical software (version 2.15.2). Correlations 
between MS risk and phenotype were assessed by using the nonparametric Wilcoxon rank-
sum test, Kruskal-Wallis chi-squared or Spearman’s rank correlation coefficient (linear 
regression). For the relapse-free interval after disease onset, additionally an extremes of 
outcome analysis using the log-rank test was performed, allowing the inclusion of censored 
untreated patients without a second relapse before the end of the follow-up period. P-values 
are represented as pAll when non-HLA and HLA risk variants were combined and pnon-HLA or 
pHLA when MS risk was based solely on the non-HLA or HLA component, respectively. The 
significance threshold, corrected for multiple testing (45 tests) was set at 0.0011. 
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Results 
The distribution of MS risk was significantly higher in MS cases compared to controls (Figure 
1(a) and (b)), either when MS risk calculation was based on all risk variants combined or 
when non-HLA and HLA risk variants were regarded separately (p<10
-15
) (Table 2). When 
including all risk variants, 3.68% of cases showed an absolute risk above 1%, compared to 
only 0.31% of controls. 
Next, we classified patients according to disease course and observed no difference in MS risk 
in patients with bout onset (BOMS) compared to primary progressive MS (PPMS) (Table 2; 
Figure 1(c) and 1(d)). Both groups of patients still presented with significantly higher genetic 
risk scores compared to the control group based on all risk variants (BOMS versus controls: 
pAll<10
-15
; PPMS versus controls: pAll=5.45*10
-15
) as well as non-HLA (BOMS versus 
controls: pnon-HLA<10
-15
; PPMS versus controls: pnon-HLA=4*10
-9
) or HLA risk variants alone 
(BOMS versus controls: pHLA<10
-15
; PPMS versus controls: pHLA=3.097*10
-7
).  
 
Figure 1. Distribution of MS risk according to disease course. 
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(a) and (b) Histograms representing MS risk distribution in patients (grey) and control subjects (white) when (a) 
including all or (b) only non-HLA loci in MS risk calculation. MS patients have higher cumulative MS risk 
scores compared to controls. The population prevalence of disease (0.001) is indicated by the dotted vertical line.  
(c) and (d) Boxplots representing the MS risk in patients, classified according to disease course, and controls 
based on (c) all risk variants or (d) non-HLA alone. Non-parametric statistical testing confirmed that MS risk in 
bout onset and primary progressive MS patients did not differ, but both groups showed significantly higher MS 
risk scores compared to controls. P-values from the Wilcoxon rank-sum test are reported. 
MS risk is plotted on a logarithmic axis.  
BOMS: bout onset MS; PPMS: primary progressive MS; N: number of individuals.  
 
The presence of OCBs in the CSF of MS patients showed, compared to absence of OCBs, a 
trend for association with a higher MS risk score based on all known risk variants 
(pAll=0.0050) (Figure 2(a); Table 2). This appears due in particular to the HLA region 
(pHLA=0.012). Despite OCB negative patients having a lower genetic risk compared to OCB 
positive patients, both groups still presented with a significantly heightened genetic burden 
compared to controls either overall (OCB+ versus controls: pAll<10
-15
; OCB- versus controls: 
pAll=2.77*10
-5
), for non-HLA (OCB+ versus controls: pnon-HLA<10
-15
; OCB- versus controls: 
pnon-HLA=5.19*10
-4
), and HLA risk variants (OCB+ versus controls: pHLA<10
-15
; OCB- versus 
controls: pHLA=0.0018). The number of OCBs present in the CSF, but not in the serum of an 
MS patient, showed a trend for association with MS risk based on HLA risk variants as well 
(pHLA=0.0028) (Table 3). Similarly, we analyzed the quantitative measure of intrathecal IgG 
synthesis and found that this IgG index is significantly associated with MS risk when only the 
HLA component is included (pHLA=3.56*10
-6
), but not when non-HLA risk variants are taken 
into account (Figure 2(c) and (d); Table 3).  
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Figure 2. Association between MS risk and CSF characteristics. 
(a) and (b) Boxplots representing MS risk in patients, classified according to OCB status, and controls 
based on (a) all risk variants or (b) non-HLA risk variants alone. MS patients display higher 
cumulative MS risk scores compared to controls, irrespective of OCB status. OCB positive patients 
display a higher MS risk score compared to OCB negative patients only when HLA is included in the 
risk model. P-values from the Wilcoxon rank-sum test are reported. 
OCB+: OCB positive MS patients; OCB-: OCB negative MS patients; N: number of individuals. 
(c) and (d) Plots showing the distribution of MS risk according to the IgG index when (c) including all 
or (d) only non-HLA risk variants. A higher genetic risk score is associated with a heightened IgG 
index when HLA risk variants are included in the model. This association is not observed when MS 
risk is based solely on non-HLA risk variants. Rho estimates and p-values from the Spearman’s rank 
correlation coefficient test are reported. 
MS risk and IgG index are plotted on logarithmic axes.  
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Analysis showed no association with relapse rate based on all risk variants (Figure 3(a)). 
However, the burden of non-HLA risk variants showed a trend for a higher baseline relapse 
rate (pnon-HLA=0.0073) (Figure 3(b), Table 3) and was significantly associated with a shorter 
relapse-free interval after disease onset (pnon-HLA=
 
0.00083). Additionally, an extremes of 
outcome survival analysis was applied comparing patients with the 10% lowest risk scores 
based on non-HLA risk variants to those with the 10% highest risk scores. Whereas a median 
relapse-free interval of 1.00 year (95% CI: 0.75 - 3.17) was seen for the high-risk group, this 
interval extended to a median of 6.91 years (95% CI: 4.00 - 11.00) for the low-risk group 
(p=0.0022) (Figure 3(c)). This effect was no longer observed when HLA risk variants were 
taken into account (Figure 3(d)). No associations were identified between MS risk and age at 
onset or severity, measured by the Multiple Sclerosis Severity Score (MSSS) (Table 3).  
 
 
Figure 3. Association between MS risk and clinical relapses. 
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(a) and (b) Plots showing the distribution of MS risk according to the baseline relapse rate when (a) including all 
or (b) only non-HLA risk variants. A higher genetic risk score is associated with an increased relapse rate when 
MS risk is based on non-HLA risk variants alone. Including HLA in the risk model attenuates this effect. Rho 
estimates and p-values from the Spearman’s rank correlation test are reported. 
MS risk is plotted on a logarithmic axis. 
(c) and (d) Survival curves for the relapse-free interval after disease onset in MS patients with the 10% highest 
(grey) and 10% lowest (black) risk scores based on all risk variants (c) or non-HLA risk variants alone (d). A 
higher genetic risk score based on non-HLA risk variants is associated with a shortened relapse free survival 
after disease onset. Censored patients are indicated. P-values from the log-rank test are reported. 
 
No association was observed between MS risk based on all risk variants and gender among 
MS patients or controls (Table 4). However, when analyzing the MS risk based on non-HLA 
or HLA risk variants separately, a trend for a higher HLA-based risk (pHLA=0.0013) and lower 
non-HLA-based risk (pnon-HLA=0.018) was observed in female compared to male MS patients. 
This was mirrored by a somewhat higher frequency of the HLA-DRB1*15:01 haplotype 
amongst female compared to male patients (allele frequency: 32.32% versus 24.58%). 
Additionally, the data indicated departure from Hardy-Weinberg equilibrium for the HLA-
DRB1*15:01 allele in female MS patients (p=0.035) These differences were not present in the 
control population .  
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Table 2. Statistical analysis of MS risk versus disease course and OCB status. 
 
  MS risk (All) 
 
MS risk (non-HLA) 
 
MS risk (HLA) 
Disease 
course N 
median 
(IQR) 
p vs 
HC 
p vs 
PPMS 
 
median 
(IQR) 
p vs 
HC 
p vs 
PPMS 
 
median 
(IQR) 
p vs 
HC 
p vs 
PPMS 
             All 
patients 842 
0.0016 
(0.00085-0.0032) < 10
-15
 - 
 
0.0014 
(0.00085-0.0022) < 10
-15
 - 
 
0.0014 
(0.00064-0.0020) < 10
-15
 - 
BOMS 727 
0.0016 
(0.00086-0.0032) < 10
-15
 0.77 
 
0.0014 
(0.00085-0.0022) < 10
-15
 0.61 
 
0.0014 
(0.00064-0.0020) < 10
-15
 0.48 
PPMS 98 
0.0014 
(0.00086-0.0032) 5.45*10
-15
 - 
 
0.0014 
(0.00090- 0.0023) 4*10
-9
 - 
 
0.0014 
(0.00064-0.0020) 3.097*10
-7
 - 
HC 321 
0.00063 
(0.00035-0.0012) - - 
 
0.00088 
(0.00054-0.0014) - - 
 
0.00064 
(0.00047-0.0011) - - 
             OCB 
status N 
median 
(IQR) 
p vs 
HC 
p vs 
OCB- 
 
median 
(IQR) 
p vs 
HC 
p vs 
OCB- 
 
median 
(IQR) 
p vs 
HC 
p vs 
OCB- 
             
OCB+ 492 
0.0016 
(0.00086-0.0032) < 10
-15
 0.0050 
 
0.0013 
(0.00085-0.0021) < 10
-15
 0.22 
 
0.0014 
(0.00064-0.0020) < 10
-15
 0.012 
OCB- 67 
0.0012 
(0.00059-0.0023) 2.77*10
-5
 - 
 
0.0012 
(0.00080-0.0017) 5.19*10
-4
 - 
 
0.00081 
(0.00064-0.0020) 0.0018 - 
HC 321 
0.00063 
(0.00035-0.0012) - - 
 
0.00088 
(0.00054-0.0014) - - 
 
0.00064 
(0.00047-0.0011) - - 
Table representing the mean MS risk scores and p-values obtained after statistical analyses (Wilcoxon rank-sum test) of MS risk versus disease course (top part of the table) or 
OCB status (bottom part of the table). To assess the effect of the HLA region, analyses were performed based on all risk variants (left), only non-HLA risk variants (middle) 
or only HLA risk variants (right); corresponding p-values are depicted as pAll, pnon-HLA and pHLA, respectively. Columns 4, 7 and 10  represent p-values when comparing patient 
groups with healthy controls, columns 5,  8 and 11 represent p-values when comparing bout onset with primary progressive MS (top part) or OCB positive with OCB negative 
MS patients (bottom part). Significant p-values are underlined, p-values depicting a trend for association are indicated in italic. 
a The group ‘All patients’ includes both patients with bout onset and primary progressive disease course as well as patients for whom exact disease course is unknown (N=17).  
BOMS: bout onset MS; PPMS: primary progressive MS; HC: healthy controls; OCB+: OCB positive MS patients; OCB-: OCB negative MS patients; N: number of 
individuals; IQR: interquartile range. 
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Table 3. Statistical analysis of MS risk and continuous variables. 
Variables pAll RhoAll pnon-HLA Rhonon-HLA pHLA RhoHLA 
MS risk vs OCB count 0.069 0.11 0.34 -0.060 0.0028 0.18 
MS risk vs IgG index 0.013 0.15 0.50 -0.041 3.56*10
-6
 0.28 
MS risk vs relapse rate 0.16 0.088 0.0073 0.17 0.44 -0.05 
MS risk vs relapse-free interval 0.25 -0.076 0.00083 -0.22 0.092 0.11 
MS risk vs AAO 0.34 -0.033 0.70 -0.014 0.30 -0.036 
MS risk vs MSSS 0.18 0.053 0.35 0.036 0.49 0.027 
Table representing p-values obtained after statistical analyses (Spearman’s rank correlation) of the variables depicted in column 1. To assess the effect of the HLA region, 
analyses were performed including all risk variants (pAll, RhoAll), only non-HLA (pnon-HLA, Rhonon-HLA) or only HLA risk variants (pHLA, RhoHLA). Significant p-values are 
underlined; p-values depicting a trend for association are indicated in italic.  
OCB count: number of oligoclonal bands present in the cerebrospinal fluid, but not in the serum of an MS patient; IgG index: immunoglobulin G index; AAO: age at onset; 
MSSS: MS severity score; Rho: Spearman’s rank correlation coefficient. 
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Table 4. Comparison of MS risk between men and women. 
  
MS risk (All) 
 
MS risk (non-HLA) 
 
MS risk (HLA) 
Gender patients   N Median (IQR) p   Median (IQR) p   Median (IQR) p 
Men 
 
299 
0.0016  
(0.00084-0.0031) 0.65   
0.0015  
(0.00089-0.0024) 0.018   
0.00081  
(0.00064-0.0020) 0.0013 
Women   543 
0.0016  
(0.00086-0.0032)     
0.0013  
(0.00083-0.0020) 
  
0.0014  
(0.00064-0.0020) 
 Gender controls 
 
N Median (IQR) p 
 
Median (IQR) p   Median (IQR)  p 
Men 
 
153 
0.00063  
(0.00037-0.0012) 0.70 
 
0.00090  
(0.00050-0.0015) 0.69   
0.00064  
(0.00047-0.0011) 0.75 
Women   168 
0.00063  
(0.00035-0.0011)     
0.00085  
(0.00054-0.0013) 
  
0.00064  
(0.00047-0.0011) 
 Table representing the mean MS risk and p-values obtained after statistical analyses (Wilcoxon rank-sum test) of MS risk versus gender in MS patients (top part of the table) 
and controls (bottom part of the table). To assess the effect of the HLA region, analyses were performed based on all risk variants (left), only non-HLA risk variants (middle) 
and only HLA risk variants (right); corresponding p-values are depicted as pAll,  pnon-HLA and pHLA, respectively. P-values depicting a trend for association are indicated in 
italic.  
N: number of individuals IQR: interquartile range.  
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Discussion 
In recent years, large-scale collaborations have led to the identification of four classical HLA 
and 110 non-HLA loci that are associated with susceptibility to MS.
2-4
 Very few of these risk 
variants have been found to be individually associated with disease phenotype (i.e. disease 
course, severity, age at onset and CSF antibody production). Previous studies did show that 
patients carrying HLA-DRB1*15:01 are more likely to develop disease at an earlier age
2,17,18
 
and are more likely to be OCB positive.
19,20
 This paucity of individual associations has led 
research groups to investigate whether the cumulative effect of these variants influences 
disease phenotype.
7-10
 In the present study we elaborated on these studies by integrating 
currently known MS susceptibility loci
2,3 
in the risk model. We applied a weighted genetic 
risk score to account for the different effect sizes. The model was based on that provided by 
Sawcer and Wason,
16
 including allele frequencies and disease prevalence in order to estimate 
an individual’s genetic risk to develop MS. The distribution of MS risk shows that even 
among MS patients, the genetic risk never exceeds 10% and only 3.68% of cases have risks 
above 1% when including all MS susceptibility loci. This underlines the findings from 
previous studies
5,6,11
 indicating that the cumulative genetic risk score is not applicable to 
predict whether or not someone will develop MS.  
The clinical course of MS can be classified as bout onset MS, i.e. relapsing-remitting or 
secondary progressive MS, or primary progressive MS.
1
 Progressive onset is known to be 
associated with a later age at disease onset and an increased male to female ratio compared to 
bout onset.
21
 We observed an increased MS risk in patients compared to controls, but not 
between patients with a different disease course. This is in agreement with previous studies 
based on a smaller number of risk loci in which no difference in MS risk was observed 
between bout onset and primary progressive MS patients,
2,7-10
 except for a difference between 
these disease course groups in male patients only in one study.
10
 Our findings also correspond 
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to what is seen in family studies, where it was shown that affected family members do not 
necessarily have the same clinical course,
22 
but do present with similar genetic risk scores.
7,8
  
A pathological hallmark of MS is intrathecal IgG synthesis, which can be measured in a 
qualitative (OCB status) or quantitative (IgG index) way. In this study we observed an 
increased MS risk in OCB positive compared to OCB negative patients and a positive 
association with IgG index. These associations were mainly driven by the HLA region. This is 
in line with previous results on a smaller set of risk variants
9,20
 and with the reported 
association of HLA-DRB1*15:01 with antibody levels in the CSF
19,20
. Our data indicate that 
most of the genetic risk factors influence disease susceptibility without affecting intrathecal 
IgG levels. The contrary is also possible, with the IGHC locus which is found to be associated 
with the IgG index, without any association with MS susceptibility.
23
 
The aforementioned results indicate that groups that were previously seen as possibly 
different MS subgroups, namely PPMS and OCB negative MS, share the same genetic risk 
variants as bout onset and OCB positive MS, with the exception of HLA-DRB1*15:01 that is 
more strongly associated with OCB positive MS.  
Although not much is known about the effect of genetic variation on relapse rate in MS 
patients,
24-26
 previous studies have shown a negative correlation with age at onset and disease 
duration
27,28
 whereas no consistent effect on disability progression could be determined.
29
 Our 
results suggest that a higher MS risk based on non-HLA risk variants is associated both with a 
higher relapse rate and a shorter relapse-free interval after disease onset. In agreement with 
previous studies that failed to show an association between relapse rate or the relapse-free 
interval after disease onset and HLA-DRB1*15:01,
25,26,30
 this effect was no longer significant 
when HLA was included in the risk calculation. These results suggest a role for non-HLA risk 
variants in the inflammatory processes underlying clinical relapses. In the current study, we 
included patients who were followed up for a minimum of three months. This may have 
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limitations for the exact estimation of the relapse rate, but has the advantage to rank patients 
with high activity, needing early treatment, high in our non-parametric statistical test. 
In the current study no association was observed between the cumulative genetic risk of MS 
and age at disease onset. This extends the studies by Gourraud et al.
7 
and van Pelt et al..
31
 The 
latter observed a comparable genetic risk score, based on 57 non-HLA risk variants and HLA-
DRB1*15:01, in pediatric and adult onset MS. In contrast, the study of Harbo et al.
9
 did 
observe an earlier age at onset in patients displaying a higher MS risk score, although this 
finding mainly reflected the known association of HLA-DRB1*15:01 with lower age at 
onset.
2
  
The Multiple Sclerosis Severity Score
32
 (MSSS) was preferred over the Expanded Disability 
Status Scale (EDSS) to measure severity, since it corrects EDSS for disease duration. In 
accordance with previous studies,
7,9
 no association was observed in the present study. This 
seems to indicate that genetic risk variants that influence susceptibility to MS, do not affect 
severity.  
We observed a slightly higher burden of non-HLA risk variants in male and of HLA risk 
variants in female patients. These effects were not present in the control population. Since 
women tend to have an increased intrinsic susceptibility to MS, it has been suggested that 
men may require a greater number of risk factors to cross the clinical threshold to develop 
disease.
33,34
 This has been demonstrated by an increased transmission of MS from affected 
fathers to their children compared to mothers, but this parent of origin effect has been subject 
of debate with different studies showing opposing results.
33-35
 The increased HLA-based risk 
in female compared to male MS patients is due to the higher frequency of HLA-DRB1*15:01 
in female (32.32%) compared to male (24.58%) patients observed in our study population. 
This is in agreement with a longstanding discussion in the literature, reporting an increased 
frequency of HLA-DRB1*15:01 in women,
2,17,36-38
 a higher transmission of HLA-
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DRB1*15:01 exclusively in female-female patient pairs
37
 or a departure of Hardy-Weinberg 
equilibrium in female but not male patients.
2
 
In this study, we included four HLA and 106 non-HLA risk variants for MS in order to 
calculate the cumulative genetic risk score and assess the relationship with disease phenotype. 
No terms for interaction or environmental risk factors were included, since knowledge of 
interactions in MS is limited and exposure to environmental risk factors is difficult to record 
in retrospective studies.  
In conclusion, a cumulative genetic risk score based on known MS risk variants is increased 
in MS patients, irrespective of disease course or OCB status, compared to control subjects. 
Whereas a high accumulation of non-HLA risk variants is associated with an increased 
relapse rate and shortened relapse-free interval after disease onset, OCB status and IgG index 
seem to be influenced mainly by the presence of HLA risk loci. We propose that the 
combined effect of non-HLA risk variants favours inflammation that is associated with 
relapses. HLA risk variants on the other hand, are often disease-specific and may drive an 
inflammatory reaction to a particular target. The associations may aid us to further explore the 
role of genetic risk variants in clinical expression of MS.  
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Appendix 1. Description of variants used for MS risk calculation. 
Chr SNP ID Gene proxy r² RA RAF OR OR_BB OR_Bb OR_bb 
1 rs3748817 MMEL1 
  
A 0.64 1.14 1.09 0.96 0.84 
1 rs3007421 PLEKHG5 
  
A 0.12 1.12 1.22 1.09 0.97 
1 rs12087340 BCL10, DDAH1 
  
A 0.09 1.22 1.43 1.17 0.96 
1 rs11587876 DDAH1 
  
A 0.79 1.12 1.05 0.93 0.83 
1 rs41286801 EVI5 
  
A 0.14 1.20 1.36 1.13 0.94 
1 rs7552544 VCAM1, EXTL2 
  
A 0.56 1.08 1.07 0.99 0.92 
1 rs11581062 VCAM1 
  
G 0.29 1.05 1.07 1.02 0.97 
1 rs6677309 CD58 
  
A 0.88 1.34 1.06 0.79 0.59 
1 rs666930 PHGDH 
  
G 0.53 1.09 1.08 0.99 0.91 
1 rs2050568 FCRL1 
  
G 0.53 1.08 1.07 0.99 0.92 
1 rs35967351 SLAMF7 
  
A 0.67 1.09 1.06 0.97 0.89 
1 rs1359062 RGS21, RGS1 
  
C 0.82 1.18 1.06 0.90 0.76 
1 rs55838263 C1orf106 
  
A 0.71 1.12 1.07 0.95 0.85 
2 rs4665719 CENPO 
  
G 0.25 1.09 1.14 1.04 0.96 
2 rs2163226 HAAO, ZFP36L2 
  
A 0.71 1.10 1.05 0.96 0.87 
2 rs842639 FLJ16341 
  
A 0.65 1.11 1.07 0.97 0.87 
2 rs7595717 CNRIP1, PLEK 
  
A 0.26 1.10 1.15 1.04 0.95 
2 rs17174870 MERTK 
  
G 0.76 1.03 1.01 0.98 0.96 
2 rs9967792 STAT4 
  
G 0.62 1.11 1.08 0.97 0.88 
2 rs9989735 SP140 
  
C 0.18 1.17 1.29 1.10 0.94 
3 rs11719975 SATB1, KCNH8 
  
C 0.27 1.09 1.13 1.04 0.95 
3 rs2371108 EOMES 
  
A 0.38 1.08 1.10 1.02 0.94 
3 rs1813375 EOMES, CMC1 
  
A 0.47 1.15 1.15 1.00 0.87 
3 rs4679081 CCR4, GLB1 
  
G 0.52 1.08 1.07 1.00 0.92 
3 rs9828629 FOXP1 
  
G 0.62 1.08 1.06 0.98 0.91 
3 rs2028597 CBLB 
  
G 0.92 1.04 1.01 0.97 0.93 
3 rs1131265 TIMMDC1 
  
C 0.80 1.19 1.07 0.90 0.75 
3 rs1920296 IQCB1 
  
C 0.64 1.14 1.09 0.96 0.84 
3 rs2255214 ILDR1, CD86 
  
C 0.52 1.11 1.10 0.99 0.90 
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3 rs9282641 CD86 
  
G 0.92 1.12 1.02 0.91 0.81 
3 rs1014486 IQCJ-SCHIP1, IL12A 
  
G 0.43 1.11 1.12 1.01 0.91 
4 rs7665090 NFKB1, MANBA 
  
G 0.52 1.08 1.08 1.00 0.92 
4 rs2726518 TET2 
  
C 0.55 1.09 1.08 0.99 0.91 
5 rs6881706 IL7R, CAPSL 
  
C 0.72 1.12 1.06 0.95 0.85 
5 rs6880778 DAB2, PTGER4 
  
G 0.60 1.10 1.08 0.98 0.89 
5 rs71624119 ANKRD55 
  
G 0.76 1.12 1.05 0.94 0.84 
5 rs756699 VDAC1, TCF7 
  
A 0.87 1.12 1.03 0.92 0.82 
5 imm_5_141486748
a NDFIP1 rs6874308 0.99 A
b 
0.61 1.07 1.05 0.98 0.92 
5 rs2546890 LOC285626 
  
A 0.52 1.06 1.06 1.00 0.94 
6 rs17119 CD83, JARID2 
  
A 0.81 1.11 1.04 0.94 0.84 
6 rs941816 PXT1 
  
G 0.18 1.13 1.22 1.08 0.95 
6 rs72928038 BACH2 
  
A 0.17 1.11 1.19 1.07 0.96 
6 rs802734 THEMIS, PTPRK 
  
A 0.69 1.03 1.02 0.99 0.96 
6 rs11154801 AHI1 
  
A 0.37 1.11 1.14 1.03 0.92 
6 rs17066096 IL20RA, IL22RA2 
  
G 0.23 1.14 1.22 1.07 0.94 
6 rs7769192 OLIG3, TNFAIP3 
  
G 0.55 1.08 1.07 0.99 0.92 
6 rs67297943 TNFAIP3, PERP 
  
A 0.78 1.12 1.05 0.94 0.84 
6 rs212405 TAGAP, FNDC1 
  
T 0.62 1.15 1.11 0.96 0.84 
7 rs1843938 CARD11, SDK1 
  
A 0.44 1.08 1.09 1.01 0.93 
7 rs706015 SKAP2, HOXA1 
  
C 0.18 1.14 1.24 1.08 0.95 
7 rs917116 JAZF1 
  
C 0.20 1.12 1.20 1.07 0.95 
7 rs60600003 ELMO1 
  
C 0.10 1.16 1.30 1.12 0.97 
7 rs354033 ZNF767 
  
G 0.74 1.03 1.02 0.99 0.96 
8 rs1021156 PKIA, ZC2HC1A 
  
A 0.24 1.12 1.18 1.06 0.94 
8 rs2456449 PCAT1, POU5F1B 
  
G 0.36 1.10 1.13 1.02 0.93 
8 rs4410871 MIR1204, PVT1 
  
G 0.72 1.12 1.06 0.95 0.85 
8 rs759648 PVT1, MIR1208 
  
C 0.31 1.09 1.13 1.03 0.95 
10 rs2104286 IL2RA 
  
A 0.72 1.21 1.10 0.91 0.75 
10 rs793108 ZNF438, ZEB1-AS1 
  
A 0.50 1.09 1.09 1.00 0.92 
10 rs2688608 CAMK2G, C10orf55 
  
A 0.55 1.07 1.06 0.99 0.93 
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10 rs1782645 ZMIZ1 
  
A 0.43 1.09 1.10 1.01 0.93 
10 rs7923837 HHEX, EXOC6 
  
G 0.61 1.11 1.08 0.97 0.88 
11 rs7120737 AGBL2 
  
G 0.15 1.13 1.23 1.09 0.96 
11 rs34383631 CD6, CD5 
  
A 0.40 1.11 1.13 1.02 0.92 
11 rs694739 PRDX5, CCDC88B 
  
A 0.62 1.08 1.06 0.98 0.91 
11 rs533646 TREH, DDX6 
  
G 0.68 1.10 1.06 0.96 0.88 
11 rs9736016 DDX6, CXCR5 
  
T 0.63 1.10 1.07 0.97 0.89 
11 rs523604 CXCR5 
  
A 0.53 1.09 1.08 0.99 0.91 
12 rs1800693 TNFRSF1A 
  
G 0.40 1.14 1.17 1.02 0.90 
12 rs12296430 LTBR, CD27-AS1 
  
C 0.19 1.14 1.23 1.08 0.95 
12 rs11052877 CD69 
  
G 0.36 1.10 1.13 1.02 0.93 
12 rs201202118 TSFM rs10431552 1.00 G
b 
0.67 1.14 1.09 0.95 0.84 
12 rs7132277 PITPNM2 
  
A 0.19 1.10 1.17 1.06 0.96 
13 rs4772201 MIR548AN, TM9SF2 
  
A 0.82 1.12 1.04 0.93 0.83 
14 rs2236262 ZFP36L1 
  
A 0.50 1.08 1.08 1.00 0.92 
14 rs4903324 JDP2, BATF 
  
A 0.19 1.10 1.17 1.06 0.96 
14 rs74796499 GALC 
  
C 0.95 1.31 1.02 0.78 0.60 
14 rs12148050 TRAF3 
  
A 0.35 1.08 1.10 1.02 0.95 
15 rs59772922 MORF4L1, CTSH 
  
A 0.83 1.11 1.03 0.93 0.84 
15 rs8042861 IQGAP1 
  
A 0.44 1.08 1.09 1.01 0.93 
16 rs2744148 SOX8, SSTR5-AS1 
  
G 0.18 1.09 1.15 1.06 0.97 
16 rs12927355 CLEC16A 
  
G 0.68 1.21 1.12 0.93 0.77 
16 rs4780346 CLEC16A, SOCS1 
  
A 0.23 1.09 1.14 1.05 0.96 
16 rs6498184 PRM1, RMI2 
  
G 0.81 1.15 1.05 0.91 0.79 
16 rs7204270 MAPK3, CORO1A 
  
G 0.50 1.09 1.09 1.00 0.91 
16 rs1886700 CDH3 
  
A 0.14 1.11 1.19 1.08 0.97 
16 rs12149527 WWOX 
  
A 0.47 1.08 1.08 1.00 0.93 
16 rs7196953 MAF, DYNLRB2 
  
A 0.29 1.08 1.11 1.03 0.96 
16 rs35929052 IRF8, LOC146513 
  
G 0.89 1.14 1.03 0.90 0.79 
17 rs12946510 GRB7, IKZF3 
  
A 0.47 1.08 1.08 1.00 0.93 
17 rs4796791 STAT3 
  
A 0.36 1.10 1.13 1.02 0.93 
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17 rs4794058 MRPL45P2, NPEPPS 
  
A 0.50 1.07 1.07 1.00 0.93 
17 rs8070345 VMP1 
  
A 0.45 1.14 1.15 1.01 0.88 
18 rs7238078 MALT1 
  
A 0.77 1.05 1.02 0.97 0.93 
19 rs1077667 TNFSF14 
  
G 0.79 1.16 1.06 0.92 0.79 
19 rs34536443 TYK2 
  
C 0.95 1.28 1.02 0.80 0.62 
19 rs2288904 SLC44A2 
  
G 0.77 1.14 1.06 0.93 0.82 
19 rs1870071 EPS15L1 
  
G 0.29 1.12 1.17 1.05 0.93 
19 rs11554159 IFI30 
  
G 0.73 1.15 1.07 0.93 0.81 
19 rs8107548 DKKL1 
  
G 0.25 1.09 1.14 1.04 0.96 
20 rs4810485 CD40 
  
A 0.25 1.08 1.12 1.04 0.96 
20 rs17785991 SLC9A8 
  
A 0.35 1.09 1.12 1.02 0.94 
20 rs2248359 CYP24A1, PFDN4 
  
G 0.60 1.07 1.05 0.99 0.92 
20 rs6062314 ZBTB46 
  
A 0.92 1.10 1.01 0.92 0.84 
22 rs2283792 MAPK1 
  
C 0.51 1.08 1.08 1.00 0.92 
22 rs470119 TYMP 
  
A 0.39 1.07 1.08 1.01 0.95 
6 HLA-DRB1*15:01 HLA-DRB1 
  
15:01 0.13
 
3.10 5.87 1.89 0.61 
6 HLA-DRB1*03:01 HLA-DRB1 
  
03:01 0.15
 
1.26 1.47 1.17 0.93 
6 HLA-DRB1*13:03 HLA-DRB1 
  
13:03 0.01
 
2.40 5.62 2.34 0.98 
6 HLA-A*02:01 HLA-A 
  
02:01 0.26
 
0.73 0.62 0.84 1.16 
Table representing 106 non-HLA and 4 classical HLA loci associated with MS susceptibility, which were used to calculate MS risk.  
When available rsIDs of the associated non-HLA variants are given in column 2. The SNPs are located in or near the genes listed in column 3. For intergenic SNPs, the 
nearest gene on each side of the variant is given. 
a 
No rsID is available for imm_5_141486748, the ID for this SNP used in the Immunochip study
1
 is given.  
b 
In the event that a proxy was used, the risk allele given in column 6 is the risk allele of the proxy SNP. Uncorrected ORs (column 8) are obtained from the Immunochip 
project
1
 for the non-HLA risk variants and from the 2011 GWAS
2
 for the HLA region. ORs are corrected according to the formula presented in the methods section.  
Chr: chromosome; SNP ID: identifier of risk single nucleotide polymorphism; RA: risk allele; RAF: risk allele frequency; OR: odds ratio, ORc_BB: corrected odds ratio for 
being homozygous for the risk allele; ORc_Bb: corrected odds ratio for being heterozygous for the risk and alternate allele; ORc_bb: corrected odds ratio for being 
homozygous for the alternate allele.  
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